Trials / Completed
CompletedNCT04735861
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
Sintilimab Plus Bevacizumab in Patients With Recurrent/Persistent Ovarian Clear Cell Carcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Ovarian clear cell carcinoma (OCCC) is one of the rare subtypes of ovarian cancer, yet its prognosis is extremely poor. Previous studies indicate that both bevacizumab and PD-1 inhibitor have clinical benefits for OCCC patients. And the combination of bevacizumab and PD-1 inhibitor has shown preliminary safety and clinical activity. Therefore, this study aims to investigate the potential benefit of combination therapy for patients with OCCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sintilimab | Sintilimab 200mg iv. q3w, up to 2 years. |
| DRUG | Bevacizumab Biosimilar IBI305 | Bevacizumab 15mg/kg iv. q3w, up to 22 cycles |
Timeline
- Start date
- 2021-04-07
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
- First posted
- 2021-02-03
- Last updated
- 2024-08-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04735861. Inclusion in this directory is not an endorsement.